# US 2026/0216106 A1 · Dosage form for intra-articular injection comprising colchicine for use in the treatment of a joint disease such as osteoarthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216106 A1
- Document ID: US20260216106A1
- Status: Published application
- Kind: A1
- Application number: 19/150,657
- Filed: 2024-01-23
- Published: 2026-07-30
- Earliest claimed: 2023-01-24
- Assignees: Pk Med
- Applicants: Pk Med
- Inventors: Farah MARZOUKI; Charles SANSON; Daniel HAYOZ; Gauthier POULIQUEN
- Web page: https://patentgrep.com/patent/US20260216106A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition under the form of a sterile and injectable dosage form having a controlled release dosage form including colchicine for treating a joint disease such as osteoarthritis, Erosive Hand Osteoarthritis and any other type of chondropathy and/or treating a pain-associated joint disease and/or protecting joint, bone and/or cartilage, by intra-articular injection of the pharmaceutical composition into a joint. The time required to release 80% by weight of the colchicine is greater than one month and the colchicine is present in a concentration ranging from 1 to 27.5 mg per ml of the sterile and injectable dosage form. The composition of the controlled release dosage form including colchicine has an adapted in vitro dissolution profile. The composition has a formulation in the form of a powder and microparticles having a polymeric matrix and forms an associated kit or article of manufacture.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A pharmaceutical composition under the form of a sterile and injectable dosage form comprising a controlled release dosage form comprising colchicine, for use in the treatment of a joint disease and/or for use in the treatment of a pain-associated joint disease and/or for use in the protection of joint, bone and/or cartilage, by intra-articular injection into a joint of said pharmaceutical composition, wherein the dissolution rate of colchicine is 80% (w/w) in more than one month, as measured according to the following protocol:
Aliquots of 20 mg of the controlled release dosage form comprising colchicine are suspended in 50 mL of Phosphate Buffer (pH 7.4) under agitation at 37° C.; then regularly throughout the release duration, supernatant of withdrawn samples is analyzed by UV at 350 nm, and wherein the colchicine is present in a concentration ranging from 1 to 27500 μg per ml of the sterile and injectable dosage form.

### Claim 22 (depends on 21)

The pharmaceutical composition for use according to claim 21, wherein the dissolution rate of colchicine is 80% (w/w) in between one to six months, two to six months or three to six months.

### Claim 23 (depends on 21)

The pharmaceutical composition for use according to claim 21, wherein the controlled release dosage form comprising colchicine is under the form of an in-situ forming depot or microparticles.

### Claim 24 (depends on 21)

The pharmaceutical composition for use according to claim 21, wherein the controlled release dosage form comprising colchicine is under the form of microparticles and wherein said microparticles comprising colchicine have a mean particle size determined by laser light diffraction measurement method equal or greater than 10 μm.

### Claim 25 (depends on 24)

The pharmaceutical composition for use according to claim 24, wherein the microparticles, which may be a mixture of microparticles of different nature, are microparticles comprising colchicine and a polymeric matrix, wherein the polymeric matrix comprises:
at least one a poly(lactic-co-glycolic acid) copolymer,
at least one poly(caprolactone), or
at least a mixture of at least a poly(lactic-co-glycolic acid) copolymer and at least a poly(caprolactone).

### Claim 26 (depends on 24)

The pharmaceutical composition for use according to claim 24, wherein the polymeric matrix further comprises one or more additional polymer(s) or copolymer(s) selected from poly(lactide) distinct from poly(lactic-co-glycolic acid) copolymer, poly(glycolide) distinct from poly(lactic-co-glycolic acid) copolymer, poly(lactide-co-caprolactone), poly(ethylene glycol), poly(ethylene oxide), PLGA-b-PEO-b-PLGA, PLGA-b-PEO, polyhydroxyalkanoates, poly(hydroxybutyrate), poly(trimethylene carbonate), poly(dioxanone), poly(valerolactone), poly(alpha-hydroxy acids), poly(lactones), poly(amino acids), polyanhydrides, poly(orthoester), poly(acetals), polyurethanes, polythioesters, polyphosphoesters, poly(ester-co-amide), poly(vinyl alcohol), PVA-g-PLGA, poly(ether ester) multiblock copolymers, polyvinyl pyrrolidone, poly(methacrylate), PEO-PPO-PEO, gelatin, heparin, chondroitin sulfate; polysaccharides such as alginates, starch, chitosan and dextrans and any combinations thereof.

### Claim 27 (depends on 24)

The pharmaceutical composition for use according to claim 24, wherein the polymeric matrix comprises at least one poly(lactic-co-glycolic acid) copolymer, at least one poly(caprolactone), or at least a mixture of at least a poly(lactic-co-glycolic acid) copolymer and at least a poly(caprolactone) in an amount of greater than 70% by weight, with respect to the total weight of the polymeric matrix.

### Claim 28 (depends on 21)

The pharmaceutical composition for use according to claim 21, wherein it is under the form of a sterile and injectable dosage form selected from a solution, a suspension, a solid implant, a semi-solid implant, a powder and an in-situ depot.

### Claim 29 (depends on 21)

The pharmaceutical composition for use according to claim 21, wherein it further comprises an anesthetic agent which may be selected from lidocaine, ropivacaine, bupivacaine, levobupivacaine, capsaicin, mepivacaine, prilocaine, pharmaceutically acceptable salts thereof and mixtures thereof.

### Claim 30 (depends on 28)

The pharmaceutical composition for use according to claim 28, wherein the colchicine is present in a concentration ranging from 1 to 27500 μg per ml of the sterile and injectable dosage form and wherein the anesthetic agent, when present, is present in a concentration ranging from 1 to 100 mg per ml of the sterile and injectable dosage form.

### Claim 31 (depends on 30)

The pharmaceutical composition according to claim 30, wherein the colchicine is present in a concentration ranging from 3 to 3600 μg per ml,
such as from 3 to 600 μg per ml when the dissolution rate of colchicine is 80% (w/w) in more than one month and less than 2 months,
such as from 9 to 1800 μg per ml when the dissolution rate of colchicine is 80% (w/w) between 2 and 4.5 months, and
such as from 18 to 3600 μg per ml when the dissolution rate of colchicine is 80% (w/w) between 4.5 months and 7 months.

### Claim 32 (depends on 21)

The pharmaceutical composition for use according to claim 21 in the treatment of osteoarthritis, Erosive Hand Osteoarthritis and any other type of chondropathy in patients, with inflammatory component, inflammatory pain or joint effusion.

### Claim 33 (depends on 21)

The pharmaceutical composition for use according to claim 21, wherein the pharmaceutical composition is further characterized in that it is effective to maintain systemic concentration of colchicine 24 hours after the intra-articular injection, lower than 5 ng/ml, and to maintain synovial concentration of colchicine after the intra-articular injection, over 1 month, greater than 0.5 ng/ml.

### Claim 34 (depends on 21)

The pharmaceutical composition for use according to claim 21, wherein it is for use in the treatment of a joint disease, such as osteoarthritis, Erosive Hand Osteoarthritis and any other type of chondropathy and/or for use in the treatment of a pain-associated joint disease and/or for use in the protection of joint, bone and/or cartilage, and/or a pain-associated osteoarthritis in a patient having renal and/or hepatic impairment, in a patient being simultaneously, separately or sequentially and non-exclusively treated by at least one active ingredient selected from: atazanavir, clarithromycin, darunavir, ritonavir, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, tipranavir, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil, cyclosporine, ranolazine, macrolides and statins or in a patient suffering from chronic comorbidities, such as hypertension, chronic kidney diseases, diabetes, cardiovascular diseases, infections, stroke, depression, peptic ulcer, metabolic syndrome and/or immunosuppression.

### Claim 35

A pharmaceutical composition under the form of a sterile and injectable dosage form comprising a controlled release dosage form comprising colchicine, wherein said pharmaceutical composition presents an in vitro dissolution profile, wherein the dissolution rate of colchicine is less than 25% (w/w), within 24 hours, and more than 80% (w/w) in more than one month, as measured according to the following protocol:
Aliquots of 20 mg of the controlled release dosage form comprising colchicine are suspended in 50 mL of Phosphate Buffer (pH 7.4) under agitation at 37° C.; then regularly throughout the release duration, supernatant of withdrawn samples is analyzed by UV at 350 nm, and wherein the colchicine is present in a concentration ranging from 1 to 27500 μg per ml of the sterile and injectable dosage form.

### Claim 36

A formulation under the form of a powder comprising a controlled release dosage form comprising colchicine, under the form of microparticles having a mean particle size determined by laser light diffraction measurement method equal or greater than 10 μm, comprising a polymeric matrix, wherein the polymeric matrix comprises at least one poly(lactic-co-glycolic acid) copolymer, at least one poly(caprolactone), or at least a mixture of at least a poly(lactic-co-glycolic acid) copolymer and at least a poly(caprolactone) in an amount of greater than 70% by weight, with respect to the total weight of the polymeric matrix.

### Claim 37 (depends on 36)

A pharmaceutical composition under the form of a sterile and injectable dosage form suitable for an intra-articular injection, obtained by mixing a formulation under the form of a powder according to the claim 36, with an aqueous injection vehicle, wherein the pharmaceutical composition comprises an excipient selected from a group consisting of a tonicity-enhancing agent, a wetting-agent, a viscosity-enhancing agent, a density-enhancing agent or a mixture thereof, and wherein said excipient may be present in the aqueous injection vehicle or in the powder.

### Claim 38

A pharmaceutical composition under the form of a sterile and injectable dosage form suitable for an intra-articular injection, comprising a controlled release dosage form comprising colchicine, under the form of microparticles having a mean particle size determined by laser light diffraction measurement method equal or greater than 10 μm comprising a polymeric matrix, wherein the polymeric matrix comprises at least one poly(lactic-co-glycolic acid) copolymer, at least one poly(caprolactone), or at least a mixture of at least a poly(lactic-co-glycolic acid) copolymer and at least a poly(caprolactone) in an amount of greater than 70% by weight, with respect to the total weight of the polymeric matrix.

### Claim 39 (depends on 37)

The pharmaceutical composition under the form of a sterile and injectable dosage form according to claim 37, wherein it is selected from a solution, a suspension, a solid implant, a semi-solid implant, a powder and an in-situ depot, and wherein colchicine is present in a concentration ranging from 1 to 27500 μg per ml, of the sterile and injectable dosage form.

### Claim 40 (depends on 23)

A kit or article of manufacture comprising, in separate compartments (i) an aqueous injection vehicle and (ii) a controlled release dosage form comprising colchicine as defined in claim 23.

### Claim 41 (depends on 40)

The kit according to claim 40, wherein the kit or article of manufacture comprises an excipient selected from a group consisting of a tonicity-enhancing agent, a wetting-agent, a viscosity-enhancing agent, a density-enhancing agent or a mixture thereof, and optionally comprises hyaluronic acid, for preparing a pharmaceutical composition suitable for an intra-articular injection.

### Claim 42 (depends on 40)

The kit according to claim 40, wherein (i) and/or (ii) comprises an anesthetic agent, which is under an immediate release dosage form.

### Claim 43 (depends on 40)

The kit or article of manufacture according to claim 40, wherein it is under the form of a vial and a prefilled syringe or of a medical device or is under the form of two separated vials.
